Il-2 linker polypeptides
Linker polypeptides with a protease-cleavable linker and VHH domain enable targeted IL-2 activation in tumors, addressing systemic toxicity and improving pharmacokinetics, thereby enhancing cancer immunotherapy.
WO2026136692A1PCT designated stage Publication Date: 2026-06-25TRUTINO BIOSCIENCES INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/060357
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-20
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Existing IL-2 therapies suffer from systemic toxicity, indiscriminate immune cell activation, short serum half-life, and inseparable activities of immunoglobulin antigen-binding domains, necessitating the development of targeted and decoupled polypeptides to address these issues.
Method used
Linker polypeptides comprising an IL-2 polypeptide sequence, a protease-cleavable linker, and an inhibitory VHH domain, allowing for targeted activation and decoupling of functions in specific extracellular environments, such as tumors, through proteolytic cleavage.
Benefits of technology
Creates gradients of IL-2 in tumor microenvironments, enhancing immune cell trafficking and immune response against cancer, while minimizing systemic effects and improving pharmacokinetics.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060357_25062026_PF_FP_ABST
Abstract
This disclosure relates to linker polypeptides. In some embodiments, the linker polypeptide comprises one or more polypeptide chains, the one or more polypeptide chains comprising: an IL-2 polypeptide sequence; a first linker, wherein the first linker is adjacent to the IL-2 polypeptide sequence and comprises a protease-cleavable polypeptide sequence; and an inhibitory polypeptide sequence comprising a VHH domain.
Need to check novelty before this filing date? Find Prior Art